TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15482245
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy (1 MHz, 1.0 W/cm², pulse 1:4, 15 min/session)
Study: 15482245
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (9 joules, 830 nm infrared laser at five points)
Study: 11136956
Drug: Vapreotide (50-microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vapreotide (50-microg intravenous bolus followed by an infusion at a rate of 50 microg per hour for five days)
Study: 11136956
Drug: Vapreotide and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vapreotide and endoscopic treatment
Study: 11136956
Drug: Endoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic treatment alone
Study: 7018328
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual treatment by emergency department nurses and residents)
Study: 31530666
Drug: Oral Semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Semaglutide 14 mg
Study: 15554315
Drug: Combined vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined vaccine 'Bubo-Kok'
Study: 11447364
Drug: MCT oil
Normalized name: Organic MCT Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT oil (60 g daily for 2 weeks)
Study: 11447364
Drug: LCT (corn
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCT (corn oil, 56 g daily for 2 weeks)
Study: 4009848
Drug: Specific operative
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific operative procedures (subclavian-vertebral roof-patch angioplasty, reimplantation, carotid-vertebral vein bypass, decompression)
Study: 31204328
Drug: Vital single
Normalized name: Vital-Chlor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vital single visit root canal treatment
Study: 31204328
Drug: Necrotic single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Necrotic single visit root canal treatment
Study: 31204328
Drug: Standardized preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized preparation technique
Study: 29551340
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine offered in the intervention group
Study: 29551340
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no vaccine offered)
Study: 19945816
Drug: Intensive telephone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive telephone counseling (bi-weekly)
Study: 19945816
Drug: Less intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less intensive telephone counseling (monthly)
Study: 12389338
Drug: Acarbose 50
Normalized name: acarbose 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 50 mg 3 times a day for 12 days (administered on day 8 before digoxin)
Study: 12389338
Drug: Digoxin 0.75
Normalized name: digoxin 0.75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 0.75 mg (administered alone)
Study: 10430713
Drug: Inhibition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibition of deep inspiration after three doses of methacholine
Study: 10430713
Drug: Inhibition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibition of deep inspiration after four doses of methacholine
Study: 1934686
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of hyaluronic acid administered intra-articularly once a week for 3 weeks
Study: 1934686
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of 6-methylprednisolone acetate administered intra-articularly once a week for 3 weeks
Study: 6179650
Drug: Dibromodulcitol 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dibromodulcitol 10 mg/kg PO weekly for 8 weeks plus bleomycin 15 mu/m2 (initially three times weekly, later changed to twice weekly for 8 weeks)
Study: 6179650
Drug: Bleomycin 15
Normalized name: bleomycin 15 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleomycin 15 mu/m2 (initially three times weekly, later changed to twice weekly for 8 weeks)
Study: 29417850
Drug: Ginger root
Normalized name: Ginger Root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger root powder (0.5 g, 2 capsules per day, 0.25 g per capsule, every 12 hours for 5 days)
Study: 27100399
Drug: Prebiotic arabinoxylan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic arabinoxylan oligosaccharides (AXOS) 10 g twice daily
Study: 14981335
Drug: High-dose Hypericum
Normalized name: Hypericum oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Hypericum perforatum extract WS 5570 (600, 900, and 1,200 mg)
Study: 9827425
Drug: Salbutamol (0.5%‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (0.5%‐1 cc) every 12 h + Placebo every 12 h
Study: 7816287
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (lithium carbonate 750 mg, 20 mmol)
Study: 3075724
Drug: Desipramine 150
Normalized name: desipramine 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine 150 mg/day
Study: 3075724
Drug: Metapramine 450
Normalized name: mosapramine
DrugBank: Mosapramine (DB13676)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Metapramine 450 mg/day
Study: 12362923
Drug: Ebastine 20
Normalized name: ebastine
DrugBank: Ebastine (DB11742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 20 mg once daily with food
Study: 12362923
Drug: Ebastine 20
Normalized name: ebastine
DrugBank: Ebastine (DB11742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 20 mg once daily without food
Study: 2089926
Drug: Nimodipine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (2 mg per hour intravenously for 7 days)
Study: 444345
Drug: suxamethonium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: suxamethonium 0.2 mg kg‐1
Study: 444345
Drug: suxamethonium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: suxamethonium 0.6 mg kg‐1
Study: 444345
Drug: hexafluorenium 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: hexafluorenium 0.3 mg kg‐1 with suxamethonium 1.0 mg kg‐1
Study: 444345
Drug: hexafluorenium 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: hexafluorenium 0.3 mg kg‐1
Study: 444345
Drug: suxamethonium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: suxamethonium 0.2 mg kg‐1 and 0.6 mg kg‐1 with or without hexafluorenium
Study: 31406051
Drug: Sugammadex 1
Normalized name: sugammadex 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 1 mg·kg‐1
Study: 31406051
Drug: Sugammadex 2
Normalized name: sugammadex 200 MG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 2 mg·kg‐1
Study: 31406051
Drug: Sugammadex 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 4 mg·kg‐1
Study: 29547835
Drug: Tivozanib (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivozanib (1.5 mg/day orally; 3 weeks on/1 week off)
Study: 29547835
Drug: Sorafenib (previous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (previous treatment)
Study: 16084809
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (wait-listed, received treatment after follow-up).
Study: 12641387
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (C‐group)
Study: 8528637
Drug: HFX RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFX RT to a total dose of 64.8 Gy (Group 1)
Study: 8528637
Drug: HFX RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFX RT with chemotherapy (100 mg carboplatin on days 1 and 2 and 100 mg etoposide on days 1-3 each week during RT) (Group 2)
Study: 8528637
Drug: HFX RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFX RT with chemotherapy (200 mg carboplatin on days 1 and 2 and 100 mg etoposide on days 1-5 of the first, third, and fifth weeks) (Group 3)
Study: 12283016
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (Mifepristone) 200 mg/day for 2 days before surgery
Study: 7297145
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ASA and DPY (ASA-DPY)
Study: 28960867
Drug: Left ventricular
Normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left ventricular end‐diastolic volume >240 mL
Study: 20864946
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (FA) treatment (5 mg/day for 4 weeks)
Study: 20864946
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (FA) treatment
Study: 18294107
Drug: Montelukast 5-10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 5-10 mg/day for 3-7 days
Study: 18294107
Drug: Albuterol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (2 puffs of metered-dose inhaler just before exercise challenge)
Study: 16087295
Drug: Intradermal capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intradermal capsaicin injections
Study: 16087295
Drug: Intradermal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal saline placebo injections
Study: 12407092
Drug: Silver diamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver diamine fluoride solution (44,800 ppm F) applied annually
Study: 12407092
Drug: Silver diamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver diamine fluoride solution (44,800 ppm F) applied annually after removal of soft carious tissues
Study: 10092314
Drug: Oxygen supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen supplementation (12 L/min for 9 hours)
Study: 7602344
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy containing cyclophosphamide
Study: 2379530
Drug: Domperidone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (15 mg) followed by Pergolide (25 micrograms) after 1 hour
Study: 2379530
Drug: Domperidone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (15 mg) followed by Placebo after 1 hour
Study: 31981856
Drug: Serial ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serial ketamine infusions
Study: 23403945
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion with 100 ml 5% dextrose/h
Study: 23403945
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusion (100 ml/h)
Study: 23403945
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline (100 ml/h)
Study: 21054229
Drug: Simultaneous sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous sinus mucosal lining elevation and placement of dental implants without graft materials
Study: 21054229
Drug: Simultaneous sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous sinus mucosal lining elevation and placement of dental implants with intraoral autogenous bone graft
Study: 20217948
Drug: Positive attitude
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Positive attitude towards medication
Study: 20217948
Drug: Medication knowledge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication knowledge
Study: 17124283
Drug: Risedronate 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 2.5 mg/day (group B)
Study: 11513817
Drug: 100-g amino
Normalized name: L-a-Amino-g-methylthiobutyric acid
DrugBank: Methionine (DB00134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100-g amino acid (AA) drink devoid of tryptophan
Study: 9635910
Drug: Piperacillin/tazobactam 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam 4 g i.v. Q6H
Study: 9635910
Drug: Imipenem 500
Normalized name: imipenem 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem 500 mg i.v. Q6H
Study: 3124598
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) for 10 days
Study: 31609293
Drug: LBW protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBW protocol (679 mg iodine/kg for men, 762 mg iodine/kg for women)
Study: 31609293
Drug: LBW protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBW protocol (620.7 mg iodine/kg)
Study: 29151034
Drug: placebo/simvastatin 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo/simvastatin 40 mg
Study: 24882567
Drug: Psilocybin (.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (.16 mg/kg)
Study: 14567819
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol 100 mug
Study: 11126207
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg t.i.d. during the first year
Study: 11126207
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg t.i.d. during the second year
Study: 8246033
Drug: Gallium nitrate
Normalized name: Gallium Nitrate
DrugBank: Gallium citrate (DB17893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gallium nitrate treatment (30 mg/m2/d for 2 weeks, followed by 2 weeks off, plus 100 mg/m2/d IV for 5 days every other month)
Study: 8246033
Drug: Gallium nitrate
Normalized name: Gallium Nitrate
DrugBank: Gallium citrate (DB17893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gallium nitrate treatment
Study: 3513669
Drug: Ketotifen 1
Normalized name: ketotifen 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 1 mg bid
Study: 23507369
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg fluoxetine and high dose folic acid (5 mg/day; n=19; Group II)
Study: 23507369
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg fluoxetine and low dose folic acid (1.5 mg/day; n=23; Group I)
Study: 16027695
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (moderate pressure)
Study: 1629748
Drug: 160/800 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160/800 mg b.i.d. orally x 3 days
Study: 1629748
Drug: 160/800 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160/800 mg i.m. x 10 days
Study: 1629748
Drug: 160/800 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160/800 mg b.i.d. orally x 20 days
Study: 6396117
Drug: Bifonazole solution
Normalized name: bifonazole
DrugBank: Bifonazole (DB04794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifonazole solution (daily for 2 weeks)
Study: 6396117
Drug: Selenium sulphide
Normalized name: Selenium sulphide
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selenium sulphide shampoo (2.5% daily for 1 week and weekly for 6 weeks)
Study: 27941065
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Atorvastatin and Evolocumab
Study: 25943660
Drug: Acetaminophen (ACT)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (ACT) 20 mg/kg
Study: 25128046
Drug: Half-dose etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Half-dose etanercept (25 mg/wk)
Study: 25128046
Drug: Full-dose etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Full-dose etanercept (50 mg/wk)
Study: 1759956
Drug: Cognitive-behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavior therapy with exposure and response prevention (CBT + ERP)
Study: 7047984
Drug: Acarbose (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (100 mg p.o.)
Study: 7047984
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 mg p.o.)
Study: 26853953
Drug: Prompt revascularization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt revascularization (PR) with intensive medical therapy (IMT)
Study: 24045979
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (600 μg)
Study: 24045979
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (10 IU)
Study: 20977608
Drug: Partial overdentures
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial overdentures supported with single immediately loaded implant in symphyseal region
Study: 17141741
Drug: Cholinergic medication
Normalized name: PARASYMPATHOMIMETICS (CHOLINERGICS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinergic medication (acetylcholinesterase inhibitor)
Study: 17141741
Drug: REM sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: REM sleep augmentation (physiological rebound)
Study: 12221896
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray, 200 mcg once daily
Study: 7828381
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg S‐nitrendipine
Study: 7828381
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg racemic nitrendipine
Study: 7828381
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg R‐nitrendipine
Study: 7828381
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg R‐nitrendipine
Study: 17398308
Drug: EPA (eicosapentaenoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA (eicosapentaenoic acid) 1800 mg daily with statin
Study: 16146489
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day topiramate
Study: 16146489
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day topiramate
Study: 10363865
Drug: Subcutaneous ardeparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous ardeparin 50 anti-Xa U/kg (low dose)
Study: 10363865
Drug: Subcutaneous ardeparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous ardeparin 100 anti-Xa U/kg (high dose)
Study: 10363865
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (including ardeparin and placebo)
Study: 6183631
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of certain foodstuffs correlated to oral ulceration
Study: 31112379
Drug: Nintedanib 150
Normalized name: nintedanib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 150 mg, administered orally twice daily
Study: 26945186
Drug: 1000 μg anisodamine
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 μg anisodamine
Study: 26945186
Drug: 2000 μg anisodamine
Normalized name: Anisodamine
DrugBank: Anisodamine (DB11785)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 μg anisodamine
Study: 26945186
Drug: 4000 μg anisodamine
Normalized name: methylcellulose
DrugBank: Methylcellulose (DB11228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4000 μg anisodamine
Study: 17665604
Drug: Fenspiride (anti-inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenspiride (anti-inflammatory drug)
Study: 7598067
Drug: Calcium supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplement (increased average calcium intake by 17.9 mmol/d or 714 mg/d)
Study: 29347
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate preparation (Citro‐Soda; Abbott) 4 g single dose
Study: 29347
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate preparation (Citro‐Soda; Abbott) 12 g single dose
Study: 29347
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate preparation (Citro‐Soda; Abbott) 4 g and 12 g doses after 3-6 days of continuous therapy every 6 hours
Study: 27447966
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC = 5, day 2) plus Paclitaxel (175 mg/m2, day 1)
Study: 27447966
Drug: Epirubicin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (75 mg/m2, day 1) plus Paclitaxel (175 mg/m2, day 2)
Study: 21121410
Drug: salbutamol 2
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: salbutamol 2 mg + bromhexine HCI 8 mg + guaiphenesin 100 mg (group A)
Study: 21121410
Drug: salbutamol 2
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: salbutamol 2 mg + guaiphenesin 100 mg (group B)
Study: 21121410
Drug: salbutamol 2
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: salbutamol 2 mg + bromhexine 8 mg (group C)
Study: 17951945
Drug: Omega-3 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 (2 gm pearls per day, given in two equal doses)
Study: 2273081
Drug: Moxonidine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine (0.25 mg)
Study: 24392848
Drug: Salmeterol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (100 μg twice daily)
Study: 12517686
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid (NA) infusion
Study: 10648307
Drug: Esmolol (ESM)
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esmolol (ESM) 1.0 mg/kg
Study: 10648307
Drug: Combination (COMB)
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (COMB) of NIC and ESM (one-half dose each)